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Background: Patients with schizoaffective disorder (SCA) experience complicated interplays of psychotic,
depressive, and manic symptoms. Paliperidone extended-release (pali ER) tablets have been shown to be
efﬁcacious in these patients, but treatment response has not been studied relative to the onset of effects
for these symptom domains.
Methods: In a pooled analysis of data from two 6-week, randomized, placebo-controlled studies, the
onset of treatment effects with oral pali ER was evaluated by symptom domain (psychosis, depression,
mania) in patients with an acute SCA exacerbation. Subjects were categorized as having prominent
psychotic (Positive and Negative Syndrome Scale score 470), depressive (Hamilton Rating Scale for
Depression–21 score Z16), or manic (Young Mania Rating Scale score Z16) symptoms at baseline.
Results: Of the 614 patients in these analyses, 597 (97.2%), 411 (66.9%), and 488 (79.5%) had prominent
psychotic, depressive, and manic symptoms at baseline, respectively. Pali ER treatment was associated
with rapid and signiﬁcant improvement of all three symptom domains versus placebo within 1 week of
initiation, regardless of whether treatment was given as monotherapy or in combination with mood
stabilizers and/or antidepressants. Adverse events were similar to those reported in the original pub-
lished studies.
Limitations: This post hoc analysis of two phase 3 trials requires conﬁrmation in prospective studies.
Conclusion: This pooled analysis suggests that treatment with pali ER is associated with rapid control of
psychotic, depressive, and manic symptoms in patients with SCA. Its ﬁndings support the beneﬁt of pali
ER as a primary treatment for the management of SCA.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The 5th edition of the Diagnostic and Statistical Manual of
Mental Disorders (DSM-5) reafﬁrms schizoaffective disorder (SCA)
as a distinct diagnostic entity characterized by a mix of symptoms,
including psychosis, depression, and mania, that are associated
with schizophrenia and affective disorders (American Psychiatric
Association [APA], 2013). SCA is about one-third as prevalent as
schizophrenia (Canuso et al., 2010) and has a prognosis that is
generally intermediate to that of schizophrenia and affective dis-
orders (Canuso et al., 2010). SCA can be disabling and requires
signiﬁcant mental health resources (Kent et al., 1995), but treat-
ment with antipsychotic medication can help manage symptomsB.V. This is an open access article u
at the time of this analysis.and improve quality of life for patients with the disorder.
Historically, symptoms of SCA have been managed with
symptom-speciﬁc concomitant medications that include anti-
psychotics, mood stabilizers, antidepressants, and anxiolytics
(Olfson et al., 2009). More recently, large, well-controlled clinical
trials of oral paliperidone extended-release (pali ER), administered
as monotherapy or in combination with mood stabilizers and/or
antidepressants, has helped establish the drug as a safe, effective,
and acute treatment of SCA (Canuso et al., 2010b; Canuso et al.,
2010a; Canuso et al., 2010c; Ortho-McNeil-Janssen Pharmaceu-
ticals, Inc., 2011). In addition, a 15-month relapse-prevention
study showed once-monthly paliperidone palmitate to be an ef-
fective long-term maintenance treatment for SCA when given as
monotherapy or in combination with mood stabilizers or anti-
depressants (Fu et al., 2015).
Because patients with SCA experience various types and seve-
rities of psychotic, depressive, and/or manic symptoms, under-
standing the extent and timing of treatment effects on each ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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concomitant therapies are important for clinical decision-making.
This pooled analysis of two large registration trials in acutely ex-
acerbated subjects with SCA evaluated the pattern and timing of
onset of pali ER treatment effects for the three primary SCA
symptom domains: psychosis, depression, and mania.2. Methods
2.1. Study design
Pooled data from two 6-week, randomized, placebo-controlled
studies of pali ER treatment versus placebo in patients with SCA
(N¼614) were examined in post hoc analyses (Canuso et al.,
2010c). Full details of these studies have been reported elsewhere
(Canuso et al., 2010b; Canuso et al., 2010a).
Brieﬂy, in study 1 (ClinicalTrials.gov identiﬁer: NCT00412373)
(Canuso et al., 2010b), acutely exacerbated subjects with SCA were
randomly assigned in a 2:1 ratio to receive 6 mg/day pali ER or
placebo. After day 4, the dosage could be adjusted in 3-mg in-
crements in a range of 3 to 12 mg/day. In study 2 (ClinicalTrials.gov
identiﬁer: NCT00397033) (Canuso et al., 2010a), acutely ex-
acerbated subjects with SCA were randomly assigned in a 1:1:1
ratio to receive lower-dose pali ER (6 mg/day, with an option to
reduce to 3 mg/day), higher-dose pali ER (12 mg/day, with an
option to reduce to 9 mg/day), or placebo. Dose adjustments were
permitted until day 15 for both studies, after which time no fur-
ther changes were allowed. Subjects could receive concomitant
treatment with mood stabilizers and/or antidepressants if they
had been treated with a stable dose within 30 days of screening
(Canuso et al., 2010b, 2010a). During screening, all other anti-
psychotic medications were discontinued in a washout period of
2 to 5 days. Subjects on stable doses of benzodiazepines at study
entry could continue at the same dose throughout the study. New
use of benzodiazepines was permitted for the ﬁrst 15 days of the
study.
The ﬁnal protocols of the original studies were approved by
participating independent ethics committees or institutional review
boards (Canuso et al., 2010b, 2010a). The studies were conducted in
accordance with the ethical principles of the Declaration of Helsinki,
and each subject provided written informed consent according to
local requirements after receiving a full explanation of the study.
2.2. Participants
Subjects in these studies were aged 18 to 65 years with a cur-
rent diagnosis of SCA, as conﬁrmed by the Structured Clinical In-
terview for DSM (DSM-IV) Disorders (American Psychiatric Asso-
ciation, 1994). All were experiencing an acute exacerbation of ill-
ness and prominent mood symptoms of o4 weeks in duration, as
evidenced by the Young Mania Rating Scale (YMRS) (Young et al.,
1978) total score of Z16 and/or the Hamilton Rating Scale for
Depression, 21-item version (HAM-D-21) (Hamilton, 1960) total
score Z16; the Positive and Negative Syndrome Scale (PANSS)
(Kay et al., 1987) total score Z60; and the PANSS score Z4 on two
or more items (ie, hostility, excitement, tension, uncooperative-
ness, or poor impulse control) (Canuso et al., 2010c).
For this analysis, subjects were categorized according to whe-
ther they displayed prominent psychotic (PANSS score 470), de-
pressive (HAM-D-21 score Z16), or manic (YMRS score Z16)
symptoms at baseline. Subjects could be included in more than
one category because baseline symptom categories were not mu-
tually exclusive. Speciﬁcally, a subject could present with promi-
nent symptoms in more than one of these domains: psychotic,
depressive, or manic.2.3. Assessments
Efﬁcacy of pali ER was assessed using the PANSS, the Clinical
Global Impressions–Severity of Illness Scale for Schizoaffective
Disorder (CGI-S-SCA), the HAM-D-21, and the YMRS. Assessments
were performed at baseline, at day 4, and at weeks 1, 2, 3, 4, and 6
(Canuso et al., 2010b, 2010a).
Analysis end points were changes from baseline to day 4 and
changes from baseline to weeks 1, 2, 3, 4, and 6 (end point) in
PANSS, HAM-D-21, and YMRS total scores. Responder rates, de-
ﬁned as subjects with a Z50% decrease from baseline in symptom
scale scores, were identiﬁed. The number of subjects who im-
proved in all three domains (psychosis, depression, and mania)
was measured at each time point and evaluated according to
treatment type (ie, pali ER or placebo, administered as mono-
therapy or in combination with mood stabilizers and/or anti-
depressants). Clinically meaningful improvements in the PANSS,
HAM-D-21, and YMRS were assessed and deﬁned as a Z30% im-
provement (European Medicines Agency and Committee for
Medicinal Products for Human Use (CHMP), 2012) or a Z10-point
decrease (Leucht et al., 2006) in the PANSS; a Z50% improvement
(Furukawa et al., 2007) or Z4-point decrease in the HAM-D-21
(Turkoz et al., 2013); and aZ50% improvement (Kemp et al., 2011)
or Z6-point decrease in the YMRS (Turkoz et al., 2013), respec-
tively. Safety assessments for this analysis included adverse event
(AE) reporting and were classiﬁed according to the Medical Dic-
tionary for Regulatory Activities (MedDRA version 9.0).
2.4. Statistical analysis
The intention-to-treat (ITT) analysis set, deﬁned as subjects
who received at least one dose of study medication and had at
least one postbaseline efﬁcacy assessment, was used for efﬁcacy
and safety assessments. Between-group differences in continuous
variables were evaluated using an analysis of covariance model
with ﬁxed effects for treatment, concomitant medication strata,
study identiﬁcation (ID), country nested within study ID, and
baseline variable. Between-group differences in categorical vari-
ables were evaluated using a Cochran–Mantel–Haenszel test that
controlled for concomitant medication strata, study ID, and
country. Percentage differences were also examined using Fisher's
exact test. Analyses of efﬁcacy data involving changes from base-
line to each assessment time point used the last-observation-
carried-forward approach. No adjustments were made for
multiplicity.3. Results
3.1. Baseline Demographics and Clinical Characteristics
The majority of subjects had overlapping symptoms of psy-
chosis, depression, and mania (Table 1). Of the 614 patients in-
cluded in these analyses, 597 (97.2%), 411 (66.9%), and 488 (79.5%)
had prominent psychotic, depressive, and manic symptoms, re-
spectively. In the overall ITT analysis set, 414 and 200 subjects
received pali ER and placebo, respectively. Baseline demographics
and clinical characteristics are outlined in Table 1. Regardless of
baseline symptoms, the mean age of subjects was 37 years, and
approximately 50% were white. All subjects had acute psychotic
symptoms at screening, and the majority (97.2%; 597/614) had
prominent, continuous psychotic symptoms at the time they were
randomly assigned to treatment. Approximately half (44.8%; 275/
614) of the subjects were receiving concomitant mood stabilizers
and/or antidepressants, with mood stabilizers used by 69.5% (191/
275) and antidepressants by 49.1% (135/275) (Canuso et al., 2010c).
Table 1
Baseline demographics and clinical characteristics (ITT population, N¼614).
Parameter Prominent psychotica Prominent depressivea Prominent manica
N¼597 N¼411 N¼488
Pali ER Placebo Pali ER Placebo Pali ER Placebo
n¼402 n¼195 n¼282 n¼129 n¼328 n¼160
Age, years, mean (SD) 37.3 (9.6) 37.2 (10.2) 37.4 (9.8) 37.1 (10.0) 37.7 (9.7) 37.4 (10.4)
Sex, n (%)
Male 242 (60.2) 117 (60.0) 156 (55.3) 74 (57.4) 202 (61.6) 98 (61.3)
Female 160 (39.8) 78 (40.0) 126 (44.7) 55 (42.6) 126 (38.4) 62 (38.8)
Race, n (%)
White 195 (48.5) 96 (49.2) 140 (49.6) 67 (51.9) 154 (47.0) 80 (50.0)
Black/African American 79 (19.6) 37 (19.0) 69 (24.5) 25 (19.4) 66 (20.1) 32 (20.0)
Asian 124 (30.9) 62 (31.8) 71 (25.2) 37 (28.7) 104 (31.7) 48 (30.0)
Other 4 (1.0) 0 (0) 2 (0.7) 0 (0) 4 (1.2) 0 (0.0)
SCA subtype, n (%)
Depressive 123 (30.8) 66 (33.8) 122 (43.7) 64 (49.6) 57 (17.5) 37 (23.1)
Bipolar 276 (69.2) 129 (66.2) 157 (56.3) 65 (50.4) 268 (82.5) 123 (76.9)
PANSS total score, mean (SD) 94.1 (12.7) 92.3 (11.7) 96.3 (12.7) 94.8 (12.2) 93.3 (13.6) 91.5 (12.2)
YMRS, mean (SD) 24.4 (10.1) 24.2 (10.1) 21.9 (10.2) 20.8 (10.1) 28.3 (7.5) 27.8 (7.5)
HAM-D-21, mean (SD) 20.7 (9.0) 19.7 (8.2) 25.2 (6.6) 24.5 (5.6) 19.1 (9.3) 17.8 (8.0)
Concomitant mood stabilizer/antidepressant use, n (%) 178 (44.3) 87 (44.6) 135 (47.9) 67 (51.9) 134 (40.9) 67 (41.9)
Monotherapy, n (%) 221 (55.0) 109 (55.9) 148 (52.5) 62 (48.1) 193 (58.8) 94 (58.8)
Suicide history, yes, n (%) 123 (30.7) 63 (32.5) 101 (35.8) 51 (39.5) 101 (30.9) 51 (32.1)
Previous hospitalization, n (%) N¼397 N¼192 N¼280 N¼126 N¼324 N¼157
333 (83.9) 168 (87.5) 234 (83.6) 110 (87.3) 277 (85.5) 139 (88.5)
CGI-S-SCA, Clinical Global Impressions-Severity of Illness Scale for Schizoaffective Disorder; HAM-D-21, Hamilton Rating Scale for Depression, 21-item version; ITT, intent-to-
treat; Pali ER, paliperidone extended-release; PANSS, Positive and Negative Syndrome Scale; SCA, schizoaffective disorder; YMRS, Young Mania Rating Scale.
aThe three groups are not mutually exclusive.
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depressants vs those receiving monotherapy, the overall mean
(standard deviation [SD]) duration of illness was 12.8 (9.2) vs 11.9
(9.6) years. The rate of duration of illness 45 years was 72.6% vs
65.8%, respectively.
In the prominent psychosis subgroup, early withdrawal from
the study occurred in 129/402 (32.1%) of pali ER–treated subjects
and 82/195 (42.1%) of placebo-treated subjects. The main reasons
for pali ER and placebo discontinuation were lack of efﬁcacy (10.1%
vs 18.5%) and subject choice (8.4% vs 9.7%). In the prominent de-
pressive subgroup, 97 (34.4%) of pali ER–treated subjects and 56
(43.4%) of placebo-treated subjects withdrew from the study; the
main reasons for discontinuation were lack of efﬁcacy (10.3% vs
17.1%) and subject choice (9.5% vs 12.4%). In the prominent manic
subgroup, 102 (31.1%) of pali ER–treated subjects and 65 (40.6%) of
placebo-treated subjects withdrew from the study; the main rea-
sons for discontinuation (pali ER vs placebo) in this subgroup were
also lack of efﬁcacy (9.8% vs 17.5%) and subject choice (8.2% vs
10.6%). The mean (SD) dose in the prominent psychotic, depres-
sive, and manic subgroups was 8.3 (2.6) mg for each group.
3.2. Efﬁcacy in Psychotic, Depressive, and Manic Symptoms
3.2.1. Prominent Psychotic Symptoms
In subjects with prominent psychosis at baseline, signiﬁcant
improvement was observed with pali ER compared with placebo
in mean change from baseline in PANSS total score from day 4 to
end point (Fig. 1A). A signiﬁcantly greater proportion of pali
ER–treated subjects were PANSS responders (Z50% reduction in
PANSS scores from baseline) relative to placebo from week 2 to
end point (Fig. 1B). The proportion of subjects with prominent
psychosis at baseline who achieved a clinically meaningful im-
provement from baseline (ie, a 10-point reduction in PANSS total
score) in psychotic symptoms throughout the course of therapy is
summarized in Fig. 1C. In this patient subgroup, manic and de-
pressive symptoms as measured by the mean change in YMRS and
HAM-D-21 scores also signiﬁcantly improved when comparedwith placebo from day 4 of treatment (pr .01 for all time points).
Subjects with prominent psychotic symptoms at baseline showed
clinically and statistically signiﬁcant improvement in mean PANSS
score compared with placebo beginning at week 1 of therapy, with
improvement continuing until week 3, followed by a plateau in
clinical response until study end point.
3.2.2. Prominent depressive symptoms
In subjects with prominent depression at baseline, signiﬁcant
improvement was observed with pali ER versus placebo in mean
change from baseline in HAM-D-21 score from day 4 to end point
(po .05) (Fig. 2A). A signiﬁcantly greater proportion of pali ER-
treated subjects were HAM-D-21 responders (Z50% reduction in
HAM-D-21 scores from baseline) relative to placebo at weeks 1, 2,
and 4 and at end point (Fig. 2B) (po .05 for selected time points).
The proportion of subjects with prominent depressive symptoms
at baseline who achieved a clinically meaningful improvement in
depressive symptoms from baseline to end point is summarized in
Fig. 2C. In this patient subgroup, mean change in YMRS and HAM-
D-21 scores also signiﬁcantly improved when compared with
placebo from week 1 of treatment (po .05 for all time points).
Subjects with prominent depressive symptoms at baseline showed
clinically and statistically signiﬁcant (po .05) improvement in
mean HAM-D-21 score compared with placebo, beginning from
week 1 of therapy and increasing until week 2, at which time there
was a plateau in improvement until end point.
3.2.3. Prominent manic symptoms
In subjects with prominent mania at baseline, signiﬁcant im-
provement (po .05) was observed with pali ER versus placebo in
mean change from baseline in YMRS score from day 4 to end point
(Fig. 3A). A signiﬁcantly (po .05) greater proportion of pali
ER–treated subjects were YMRS responders (Z50% reduction in
YMRS scores from baseline) relative to placebo fromweek 2 to end
point (Fig. 3B). The proportion of subjects with prominent manic
symptoms at baseline who achieved a clinically meaningful im-
provement from baseline in depressive symptoms throughout the
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Fig. 1. Subjects with prominent psychotic symptoms (Positive and Negative Syndrome Scale [PANSS] score 470). A. Least squares (LS) mean change from baseline in PANSS
scores. B. Percentage of responders (Z50% reduction from baseline in PANSS total score). C. Proportion of subjects with clinically meaningful improvement in PANSS scores
(Z10 point improvement). *pr .01, pali ER vs placebo. †pr .001, pali ER vs placebo. ‡po .05, Fisher's exact test, pali ER vs placebo. §po .01, Fisher's exact test, pali ER vs
placebo. LS, least squares; Pali ER, paliperidone extended-release; PANSS, Positive and Negative Syndrome Scale; SE, standard error.
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Fig. 2. Subjects with prominent depressive symptoms (HAM-D-21 Z16). A. Least squares (LS) mean change from baseline in HAM-D-21 scores. B. Percentage of responders
(Z50% decrease from baseline in HAM-D-21 score). C. Proportion of subjects with clinically meaningful improvement in HAM-D-21 scores (Z4-point improvement).
*po .05, pali ER vs placebo. †pr .001, pali ER vs placebo. ‡po .05, Fisher's exact test, pali ER vs placebo. §po .01, Fisher's exact test, pali ER vs placebo. HAM-D-21, Hamilton
Rating Scale for Depression, 21-item version; LS, least squares; Pali ER, paliperidone extended-release; SE, standard error.
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mean change in YMRS and HAM-D-21 scores also signiﬁcantly
improved when compared with placebo from day 4 of treatment
(pr .01 for all time points). Subjects with prominent manic
symptoms at baseline showed clinically and statistically signiﬁcant
improvement in mean YMRS scores compared with placebo at day
4 of therapy. Increasing improvement was observed until week 3.
Improvement plateaued fromweek 3 to end point (po .05). Results
at week 1 were not statistically signiﬁcant (p¼ .154).
3.2.4. Improvement in all symptom domains
By the end of the ﬁrst week of treatment, more than 13% of
study subjects treated with pali ER (n¼414) showedimprovements in all baseline symptom scores (PANSS r70, HAM-
D-21 r12, and YMRS r12). This number continued to increase
steadily throughout the study, up to 39% by week 6, with sig-
niﬁcant (po .05) improvements from week 3 onward compared
with placebo (Fig. 4A). This improvement in all scores was ap-
parent whether subjects were treated with pali ER as mono-
therapy or in combination with mood stabilizers and/or anti-
depressants (Fig. 4B)
3.3. Adverse events
Regardless of prominent baseline symptoms, approximately
69.0% of subjects treated with pali ER reported at least one
Table 2
Occurrence of treatment-emergent adverse events according to baseline symptoms (ITT population, N¼614).
n (%) Prominent psychotica Prominent depressivea Prominent manica
N¼597 N¼411 N¼488
Pali ER Placebo Pali ER Placebo Pali ER Placebo
n¼402 n¼195 n¼282 n¼129 n¼328 n¼160
Number of subjects with Z1 TEAE 277 (68.9) 115 (59.0) 194 (68.8) 80 (62.0) 226 (68.9) 93 (58.1)
Discontinuation due to AE 27 (6.7) 13 (6.7) 18 (6.4) 10 (7.8) 19 (5.8) 11 (6.9)
TEAE (MedDRA-preferred term)
Headache 60 (14.9) 30 (15.4) 47 (16.7) 21 (16.3) 45 (13.7) 25 (15.6)
Nausea 27 (6.7) 12 (6.2) 22 (7.8) 6 (4.7) 25 (7.6) 11 (6.9)
Dyspepsia 22 (5.5) 5 (2.6) 20 (7.1) 4 (3.1) 21 (6.4) 3 (1.9)
Dizziness 26 (6.5) 12 (6.2) 19 (6.7) 10 (7.8) 21 (6.4) 8 (5.0)
Insomnia 26 (6.5) 14 (7.2) 19 (6.7) 10 (7.8) 18 (5.5) 8 (5.0)
Tremor 32 (8.0) 7 (3.6) 15 (5.3) 5 (3.9) 28 (8.5) 5 (3.1)
Akathisia 22 (5.5) 9 (4.6) 14 (5.0) 7 (5.4) 18 (5.5) 6 (3.8)
Somnolence 21 (5.2) 4 (2.1) 16 (5.7) 3 (2.3) 15 (4.6) 3 (1.9)
Hypertonia 22 (5.5) 4 (2.1) 13 (4.6) 3 (2.3) 20 (6.1) 2 (1.3)
Sedation 20 (5.0) 7 (3.6) 12 (4.3) 4 (3.1) 19 (5.8) 7 (4.4)
Dry mouth 17 (4.2) 8 (4.1) 15 (5.3) 6 (4.7) 15 (4.6) 8 (5.0)
Constipation 17 (4.2) 5 (2.6) 15 (5.3) 4 (3.1) 12 (3.7) 5 (3.1)
AE, adverse event; ITT, intent-to-treat; MedDRA, Medical Dictionary for Regulatory Activities; Pali ER, paliperidone extended-release; TEAE, treatment-emergent adverse
event.
aThe three groups are not mutually exclusive. Gray shading indicates TEAE occurring at Z5% in the pali ER group.
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those receiving placebo (Table 2). In subjects who received pali ER,
6.7%, 6.4%, and 5.8% in the prominent psychotic, depressive, and
manic subgroups, respectively, discontinued due to an AE com-
pared with 6.7%, 7.8%, and 6.9% of subjects who received placebo,
respectively.
In the pooled database, the most frequently reported TEAEs
(Z5.0% in those receiving pali ER) among subjects receiving pali
ER versus placebo were headache (14.3% vs 14.9%, respectively),
tremor (8.1% vs 3.5%), dizziness (6.7% vs 5.9%), insomnia (6.7% vs
6.9%), nausea (6.4% vs 5.9%), akathisia (5.5% vs 4.5%), hypertonia
(5.5% vs 2.0%), dyspepsia (5.5% vs 2.5%), somnolence (5.2% vs 2.0%),
and sedation (5.0% vs 3.5%) (Canuso et al., 2010c). Of these,
headache, nausea, dyspepsia, dizziness, insomnia, tremor, and
akathisia occurred in Z5% of pali ER–treated subjects, regardless
of prominent baseline symptom.4. Discussion
Results from this study suggest that pali ER may be a core
therapy for the treatment of all symptom domains associated with
acute exacerbation of SCA. A rapid acute response was demon-
strated with pali ER, which was both clinically and statistically
signiﬁcant within 1 week of commencing therapy. Furthermore,
the treatment effect of pali ER was evident in subjects who were
receiving monotherapy or adjunctive therapy with mood stabi-
lizers and/or antidepressants. These ﬁndings are in line with the
results of previous prospective studies (Canuso et al., 2010c,
2010a), which support the use of the paliperidone molecule for the
acute management of SCA symptoms following relapse. Recent
evidence from a long-term, randomized, double-blind, relapse-
prevention study also supports the use of paliperidone as a
maintenance treatment in persons with SCA (Fu et al., 2015).
In this population of subjects with SCA experiencing acute
exacerbations, it is important to note that the three prominent
symptom subgroups were not mutually exclusive, with most
subjects exhibiting symptoms of multiple domains. This overlap of
psychotic, depressive, and manic symptoms is reﬂective of the
general SCA population and highlights the complexity of the dis-
ease. In those receiving pali ER, the initial onset of symptomaticimprovement, as measured by mean changes from baseline in
symptom scores, was rapid, with signiﬁcant differences being
evident as early as day 4 in all domains. The onset of clinically
meaningful improvements in psychotic and depressive symptoms
was also rapid, and signiﬁcant improvements in the achievement
of the more stringent end point of treatment response (Z50%
reduction from baseline in symptom scores) was observed from
week 2 onwards in all symptom domains. Taken together, these
data add to the understanding of the onset of treatment effect on
each of the symptom domains of SCA and suggest that pali ER can
be used to effectively manage these symptoms following an acute
exacerbation.
Pali ER has been previously evaluated in subjects with bipolar I
disorder and similar symptoms (ie, acute mania or mixed episodes
with or without psychotic symptoms) (Vieta et al., 2010; Berwaerts
et al., 2012, 2011). Similar to our ﬁndings, the results of two pla-
cebo-controlled trials demonstrated signiﬁcantly greater reduc-
tions from baseline in YMRS at week 3 (primary endpoint) for
monotherapy with ﬂexibly dosed pali ER 3–12 mg (13.2 vs 7.4;
po .001) (Vieta et al., 2010) and pali ER 12 mg (13.9 vs 9.9;
po .01) (Berwaerts et al., 2012) versus placebo; pali ER 3 mg and
6 mg did not separate from placebo. A 6-week adjunctive therapy
study of bipolar subjects with acute mania showed no signiﬁcant
improvement in YMRS with ﬂexibly dosed pali ER add-on to mood
stabilizers relative to mood stabilizer monotherapy (14.3 vs
13.2; p¼0.16) (Berwaerts et al., 2011).
Overall, a large proportion of subjects (44.8%) were sufﬁciently
symptomatic to enter the two studies despite receiving adjunctive
therapy with mood stabilizers and/or antidepressants, indicating
that these concomitant medications did not provide effective
control of their symptoms. The beneﬁcial effects of pali ER de-
monstrated in this study were seen regardless of whether treat-
ment was given as monotherapy or in combination with mood
stabilizers and/or antidepressants (Canuso et al., 2010c, 2010b,
2010a). The reduction in symptoms, as measured by the percen-
tage of subjects with a composite response, occurred in a slightly
higher proportion of subjects receiving pali ER monotherapy
(53.5%) compared with those receiving pali ER in combination
with mood stabilizers and/or antidepressants (45.2%) (Canuso
et al., 2010c, 2010b, 2010a). It is possible that those subjects re-
quiring adjunctive medication may be a more treatment-resistant
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quiring adjunctive medication was slightly longer than those re-
ceiving pali ER monotherapy. This is further supported by the
observation that subjects in the placebo monotherapy treatment
arm had a greater reduction in symptoms than those in the pla-
cebo adjunctive arm (Canuso et al., 2010c, 2010b, 2010a). The
smaller treatment effect of pali ER in those receiving adjunctive
medication may also reﬂect the partial efﬁcacy of adjunctive
therapy for some symptoms. This raises the possibility that ad-
junctive therapy should not be the core or backbone therapy. Ra-
ther, primary treatment might begin with the initiation of pali ER,
followed by the addition of adjunctive therapy as necessary.
The overall safety and tolerability proﬁles of pali ER appeared
similar among the different symptomatic subgroups assessed in
this study. Furthermore, the pattern of TEAEs observed in these
symptomatic subgroups was generally similar to that of the overall
study populations (Canuso et al., 2010c, 2010a) and to that of
previous short-term studies of pali ER in persons with schizo-
phrenia (Davidson et al., 2007; Kane et al., 2007; Marder et al.,
2007; Kramer et al., 2007).
There are limitations of the current analysis that should be ta-
ken into consideration. Data were analyzed from selected subjects
enrolled in two randomized, controlled trials, potentially limiting
the generalizability to broader groups of individuals with SCA who
may be encountered in clinical practice (ie, those who were ex-
cluded from these trials). Furthermore, the substantially lower pali
ER dosing in a treatment arm of one study (3 to 6 mg/day) (Canuso
et al., 2010a) relative to the overall mean dose of pali ER (8.3 mg)
seen across the three prominent symptom subgroups may have
had an impact on the overall pali ER treatment effect in this ana-
lysis. It is also important to note that this was a post hoc analysis of
pooled data from previously completed registration trials. As a
result, these ﬁndings should be considered as hypothesis-gen-
erating and will require conﬁrmation from prospective studies.
In conclusion, this post hoc analysis suggests that pali ER was
associated with signiﬁcant improvement relative to placebo in
psychotic, depressive, and manic symptom scores. The improve-
ments were observed as early as day 4, with greater responder
rates by weeks 1 and 2 in symptomatic subjects with SCA, in-
cluding those receiving adjunctive therapy with mood stabilizers
and/or antidepressants. Taken together, these ﬁndings for pali ER
provide additional knowledge and support for the clinical value of
the paliperidone molecule for the management of SCA.
Role of funding source
This research was funded by Janssen Scientiﬁc Affairs, LLC, Titusville, New
Jersey, USA.Contributors
D.-J. Fu, C. A. Bossie, H. Patel, and L. Alphs were responsible for
the design, data collection, and writing. I. Turkoz was responsible
for the design, data collection, writing, and statistical analyses. All
authors critically reviewed and revised the manuscript and ap-
proved the ﬁnal version.Conﬂicts of interest
D.-J. Fu, C. A. Bossie, and L. Alphs are employees of Janssen
Scientiﬁc Affairs, LLC, and Johnson & Johnson stockholders.
I. Turkoz is an employee of Janssen Research & Development, LLC,
and a Johnson & Johnson stockholder. H. Patel was an employee of
Janssen Scientiﬁc Affairs at the time of this analysis and is a
Johnson & Johnson stockholder.Registration
The primary studies are registered at ClinicalTrials.gov
(NCT00412373 and NCT00397033).Previous presentation
These data were presented, in part, at the 14th International
Congress on Schizophrenia Research; April 21–25, 2013: Orlando,
FL, USA.Acknowledgment
The authors thank Matthew Grzywacz, PhD, Sally Mitchell, PhD, Tricia Newell,
PhD, Maxwell Chang, BSc Hons, and ApotheCom, LLC (Yardley, PA), for their writing
and editorial assistance.References
American Psychiatric Association, 1994. Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition American Psychiatric Association, Washington, DC.
American Psychiatric Association [APA], 2013. Diagnostic and Statistical Manual of
Mental Disorders, Fifth Edition (DSM-5s), pp. 1–991.
Berwaerts, J., Lane, R., Nuamah, I.F., Lim, P., Remmerie, B., Hough, D.W., 2011. Pali-
peridone extended-release as adjunctive therapy to lithium or valproate in the
treatment of acute mania: a randomized, placebo-controlled study. J. Affect.
Disord. 129 (1–3), 252–260.
Berwaerts, J., Xu, H., Nuamah, I., Lim, P., Hough, D., 2012. Evaluation of the efﬁcacy
and safety of paliperidone extended-release in the treatment of acute mania: a
randomized, double-blind, dose-response study. J. Affect. Disord. 136 (1–2),
e51–e60.
Canuso, C.M., Kosik-Gonzalez, C., Sheehan, J., Mao, L., Kalali, A.H., 2010. Frequency of
schizoaffective disorder diagnosis in an international patient population with
psychotic disorders using the Mini-International Neuropsychaitric Interview.
Schizophr. Res. 118 (1–3), 305–306.
Canuso, C.M., Lindenmayer, J.-P., Kosik-Gonzalez, C., Turkoz, I., Carothers, J., Bossie,
C.A., Schooler, N.R., 2010a. A randomized, double-blind, placebo-controlled
study of 2 dose ranges of paliperidone extended-release in the treatment of
subjects with schizoaffective disorder. J. Clin. Psychiatry 71 (5), 587–598.
Canuso, C.M., Schooler, N., Carothers, J., Turkoz, I., Kosik-Gonzalez, C., Bossie, C.A.,
Walling, D., Lindenmayer, J.-P., 2010b. Paliperidone extended-release in schi-
zoaffective disorder: a randomized, controlled study comparing a ﬂexible dose
with placebo in patients treated with and without antidepressants and/or
mood stabilizers. J. Clin. Psychopharmacol. 30 (5), 487–495.
Canuso, C.M., Turkoz, I., Fu, D.-J., Bossie, C.A., 2010c. Role of paliperidone extended-
release in treatment of schizoaffective disorder. Neuropsychiatr. Dis. Treat. 6,
667–679.
Davidson, M., Emsley, R., Kramer, M., Ford, L., Pan, G., Lim, P., Eerdekens, M., 2007.
Efﬁcacy, safety and early response of paliperidone extended-release tablets
(paliperidone ER): results of a 6-week, randomized, placebo-controlled study.
Schizophr. Res. 93 (1–3), 117–130.
European Medicines Agency and Committee for Medicinal Products for Human Use
(CHMP), 2012. Guideline on Clinical Investigation of Medicinal Products, In-
cluding Depot Preparations in the Treatment of Schizophrenia. 〈http://www.
ema.europa.eu/docs/en_GB/document_library/Scientiﬁc_guideline/2012/10/
WC500133437.pdf〉.
Fu, D.-J., Turkoz, I., Simonson, R.B., Walling, D.P., Schooler, N.R., Lindenmayer, J.-P.,
Canuso, C.M., Alphs, L., 2015. Paliperidone palmitate once-monthly reduces risk
of relapse of psychotic, depressive, and manic symptoms and maintains func-
tioning in a double-blind, randomized study of schizoaffective disorder. J. Clin.
Psychiatry 76 (3), 253–262.
Furukawa, T.A., Akechi, T., Azuma, H., Okuyama, T., Higuchi, T., 2007. Evidence-
based guidelines for interpretation of the Hamilton Rating Scale for Depression.
J. Clin. Psychopharmacol. 27 (5), 531–534.
Hamilton, M., 1960. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry
23, 56–62.
Kane, J., Canas, F., Kramer, M., Ford, L., Gassmann-Mayer, C., Lim, P., Eerdekens, M.,
2007. Treatment of schizophrenia with paliperidone extended-release tablets:
a 6-week placebo-controlled trial. Schizophr. Res. 90, 147–161.
Kay, S.R., Fiszbein, A., Opler, L.A., 1987. The positive and negative syndrome scale
(PANSS) for schizophrenia. Schizophr. Bull. 13 (2), 261–276.
Kemp, D.E., Johnson, E., Wang, W.V., Tohen, M., Calabrese, J.R., 2011. Clinical utility
of early improvement to predict response or remission in acute mania: focus on
olanzapine and risperidone. J. Clin. Psychiatry 72 (9), 1236–1241.
Kent, S., Fogarty, M., Yellowlees, P., 1995. Heavy utilization of inpatient and out-
patient services in a public mental health service. Psychiatr. Serv. 46 (12),
1254–1257.
Kramer, M., Simpson, G., Maciulis, V., Kushner, S., Vijapurkar, U., Lim, P., Eerdekens,
M., 2007. Paliperidone extended-release tablets for prevention of symptom
D.-J. Fu et al. / Journal of Affective Disorders 193 (2016) 381–390390recurrence in patients with schizophrenia: a randomized, double-blind, pla-
cebo-controlled study. J. Clin. Psychopharmacol. 27 (1), 6–14.
Leucht, S., Kane, J.M., Etschel, E., Kissling, W., Hamann, J., Engel, R.R., 2006. Linking
the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 31
(10), 2318–2325.
Marder, S.R., Kramer, M., Ford, L., Eerdekens, E., Lim, P., Eerdekens, M., Lowy, A.,
2007. Efﬁcacy and safety of paliperidone extended-release tablets: results of a
6-week, randomized, placebo-controlled study. Biol. Psychiatry. 62 (12),
1363–1370.
Olfson, M., Marcus, S.C., Wan, G.J., 2009. Treatment patterns for schizoaffective
disorder and schizophrenia among Medicaid patients. Psychiatr. Serv. 60 (2),
210–216.Ortho-McNeil-Janssen Pharmaceuticals, 2007. Inc. Invega (paliperidone) extended-
release tablets. 2011. Titusville, NJ.
Turkoz, I., Fu, D.-J., Bossie, C.A., Sheehan, J.J., Alphs, L., 2013. Relationship between
the clinical global impression of severity for schizoaffective disorder scale and
established mood scales for mania and depression. J. Affect. Disord. 150 (1),
17–22.
Vieta, E., Nuamah, I.F., Lim, P., Yuen, E.C., Palumbo, J.M., Hough, D.W., Berwaerts, J.,
2010. A randomized, placebo- and active-controlled study of paliperidone ex-
tended release for the treatment of acute manic and mixed episodes of bipolar I
disorder. Bipolar Disord. 12 (3), 230–243.
Young, R.C., Biggs, J.T., Ziegler, V.E., Meyer, D.A., 1978. A rating scale for mania:
reliability, validity and sensitivity. Br. J. Psychiatry 133, 429–435.
